keyword
https://read.qxmd.com/read/38639044/genomic-catastrophe-chromothripsis-and-polyploidy-correlates-with-tumor-distribution-in-extrauterine-high-grade-serous-carcinoma
#1
JOURNAL ARTICLE
Ju-Yoon Yoon, Aarti Sharma, Azra H Ligon, Rebecca G Ramesh, T Rinda Soong, Wa Xian, David B Chapel, Christopher P Crum
Most extrauterine high-grade serous carcinomas (HGSCs) are thought to develop first in the distal fallopian tube. Most models of HGSC assume origin from relatively stable, noninvasive serous tubal intraepithelial carcinomas. However, widespread tumor involvement in the absence of a serous tubal intraepithelial carcinoma could occur after catastrophic genomic events (CGEs; such as chromothripsis or polyploidy). Twenty-six HGSCs assigned to fallopian tube (n = 9, group 1) and/or ovary (n = 9, group 2), and primary peritoneal (n = 8, group 3) were assessed by microarray (Oncoscan)...
April 18, 2024: American Journal of Surgical Pathology
https://read.qxmd.com/read/38513168/high-concordance-of-different-assays-in-the-determination-of-homologous-recombination-deficiency-associated-genomic-instability-in-ovarian-cancer
#2
JOURNAL ARTICLE
Nicole Pfarr, Karin von Schwarzenberg, Dario Zocholl, Sabine Merkelbach-Bruse, Janna Siemanowski, Eva-Maria Mayr, Sylvia Herold, Karsten Kleo, Lukas C Heukamp, Eva-Maria Willing, Michael Menzel, Ulrich Lehmann, Stephan Bartels, Shounak Chakraborty, Gustavo Baretton, Melanie C Demes, Claudia Döring, Daniel Kazdal, Jan Budczies, Roland Rad, Peter Wild, Yann Christinat, Thomas McKee, Peter Schirmacher, David Horst, Reinhard Büttner, Albrecht Stenzinger, Jalid Sehouli, Claudia Vollbrecht, Michael Hummel, Elena I Braicu, Wilko Weichert
PURPOSE: Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown promising clinical results in the treatment of ovarian cancer. Analysis of biomarker subgroups consistently revealed higher benefits for patients with homologous recombination deficiency (HRD). The test that is most often used for the detection of HRD in clinical studies is the Myriad myChoice assay. However, other assays can also be used to assess biomarkers, which are indicative of HRD, genomic instability (GI), and BRCA1 / 2 mutation status...
March 2024: JCO Precision Oncology
https://read.qxmd.com/read/38351155/pediatric-spinal-ependymoma-with-chromothripsis-of-chromosome-6-a-case-report-and-review-of-the-literature
#3
REVIEW
Keela R Scott, Melissa A Gener, Elena A Repnikova
BACKGROUND: Ependymomas are the third most common central nervous system tumor in the pediatric population; however, spinal ependymomas in children are rare. Ependymomas affecting the spinal cord most frequently occur in adults of 20-40 years of age. The current World Health Organization classification system for ependymomas is now composed of ten different entities based on histopathology, location, and molecular studies, with evidence that the new classification system more accurately predicts clinical outcomes...
February 14, 2024: Journal of Medical Case Reports
https://read.qxmd.com/read/38067228/concordance-between-three-homologous-recombination-deficiency-hrd-assays-in-patients-with-high-grade-epithelial-ovarian-cancer
#4
JOURNAL ARTICLE
Elena Fountzilas, Kyriaki Papadopoulou, Thomas Chatzikonstantinou, Georgios Karakatsoulis, Pantelis Constantoulakis, Aikaterini Tsantikidi, Georgios Tsaousis, Sofia Karageorgopoulou, Anna Koumarianou, Davide Mauri, Anastasios Ntavatzikos, Zacharenia Saridaki, Georgios Petrakis, Florentia Fostira, George Fountzilas, Michalis Liontos
Our aim was to evaluate the concordance between the Myriad MyChoice and two alternative homologous recombination deficiency (HRD) assays (AmoyDx HRD Focus NGS Panel and OncoScan™) in patients with epithelial ovarian cancer (EOC). Tissue samples from 50 patients with newly diagnosed EOC and known Myriad MyChoice HRD status were included. DNA aliquots from tumor samples, previously evaluated with Myriad MyChoice and centrally reassessed, were distributed to laboratories to assess their HRD status using the two platforms, after being blinded for the Myriad MyChoice CDx HRD status...
November 22, 2023: Cancers
https://read.qxmd.com/read/37902999/clinical-implication-of-genetic-intratumor-heterogeneity-for-targeted-therapy-in-head-and-neck-cancer
#5
JOURNAL ARTICLE
Signe Buhl Gram, Daniela Alosi, Frederik Otzen Bagger, Olga Østrup, Christian von Buchwald, Jeppe Friborg, Irene Wessel, Ivan Richter Vogelius, Kristoffer Rohrberg, Jacob Høygaard Rasmussen
Background: Genomic profiling is increasingly used both in therapeutic decision-making and as inclusion criteria for trials testing targeted therapies. However, the mutational landscape may vary across different areas of a tumor and intratumor heterogeneity will challenge treatments or clinical decisions based on single tumor biopsies. The purpose of this study was to assess the clinical relevance of genetic intratumor heterogeneity in head and neck squamous cell carcinomas (HNSCC) using the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)...
October 30, 2023: Acta Oncologica
https://read.qxmd.com/read/37894345/deletions-of-cdkn2a-and-mtap-detected-by-copy-number-variation-array-are-associated-with-loss-of-p16-and-mtap-protein-in-pleural-mesothelioma
#6
JOURNAL ARTICLE
Bart Vrugt, Michaela B Kirschner, Mayura Meerang, Kathrin Oehl, Ulrich Wagner, Alex Soltermann, Holger Moch, Isabelle Opitz, Peter J Wild
CDKN2A deletion is a common alteration in pleural mesothelioma (PM) and frequently associated with co-deletion of MTAP . Since the standard detection method for CDKN2A deletion and FISH analysis is relatively expensive, we here investigated the suitability of inexpensive p16 and MTAP IHC by comparing concordance between IHC and OncoScan CNV arrays on samples from 52 PM patients. Concordance was determined using Cohen's kappa statistics. Loss of CDKN2A was associated with co-deletion of MTAP in 71% of cases...
October 13, 2023: Cancers
https://read.qxmd.com/read/37809048/rediscore-prospective-validation-of-a-pipeline-for-homologous-recombination-deficiency-analysis
#7
JOURNAL ARTICLE
Aikaterini Tsantikidi, Konstantinos Papazisis, Theofanis Floros, Maria Gazouli, Eirini Papadopoulou, Georgios Tsaousis, Georgios Nasioulas, Andra Mester, Kubelac Paul Milan, Bogdan Gozman, Vlad Afrasanie, Dana Lucia Stanculeanu, Oana Trifanescu, Florentina Pescaru, Claudia Militaru, Christos Papadimitriou
Tumors harboring homologous recombination deficiency (HRD) are considered optimal candidates for poly(ADP-ribose) polymerase 1 (PARP) inhibitor treatment. Such deficiency can be detected by analyzing breast cancer type ( BRCA)1/2 gene mutations, as well as mutations in other genes of the homologous recombination pathway. The algorithmic measurement of the HRD effect by identifying genomic instability (GI) has been used as biomarker. As compared with the direct measurement of somatic gene alterations, this approach increases the number of patients who could benefit from PARP inhibitor treatment...
November 2023: Oncology Letters
https://read.qxmd.com/read/37501528/-mdm2-amplification-status-in-a-cohort-of-well-characterized-myxofibrosarcoma-a-clinicopathologic-analysis-of-22-tumors
#8
JOURNAL ARTICLE
Nooshin K Dashti, Judith Jebastin Thangaiah, Troy Gliem, Darlene Knutson, Sara Kloft-Nelson, Susan M Armstrong, Ahmed Bakhshwin, Patricia Greipp, Karen J Fritchie
Myxofibrosarcomas (MFS) present as slowly enlarging superficial masses in elderly patients. Even though these tumors fail to exhibit a distinct immunophenotype, diagnosis is straightforward when they present in subcutaneous tissue. Intramuscular MFS, however, are more challenging to diagnose as the differential also includes dedifferentiated liposarcoma with myxoid features. The vast majority of dedifferentiated liposarcomas show MDM2 amplification, whereas limited data exists as to the MDM2 status of MFS. We sought to explore the rate of MDM2 amplification in cases of classic MFS...
July 27, 2023: International Journal of Surgical Pathology
https://read.qxmd.com/read/37460928/genomic-analyses-of-germline-and-somatic-variation-in-high-grade-serous-ovarian-cancer
#9
JOURNAL ARTICLE
A W Adamson, Y C Ding, L Steele, L A Leong, R Morgan, M T Wakabayashi, E S Han, T H Dellinger, P S Lin, A A Hakim, S Wilczynski, C D Warden, S Tao, V Bedell, M C Cristea, S L Neuhausen
BACKGROUND: High-grade serous ovarian cancers (HGSCs) display a high degree of complex genetic alterations. In this study, we identified germline and somatic genetic alterations in HGSC and their association with relapse-free and overall survival. Using a targeted capture of 557 genes involved in DNA damage response and PI3K/AKT/mTOR pathways, we conducted next-generation sequencing of DNA from matched blood and tumor tissue from 71 HGSC participants. In addition, we performed the OncoScan assay on tumor DNA from 61 participants to examine somatic copy number alterations (SCNA)...
July 17, 2023: Journal of Ovarian Research
https://read.qxmd.com/read/37400764/genomic-landscapes-of-ovarian-clear-cell-carcinoma-from-latin-countries-reveal-aberrations-linked-to-survival-and-progression
#10
JOURNAL ARTICLE
Mariana de Paiva Batista, Martín Roffé, Ignacio Romero, José Antonio López-Guerrero, Carmen Illueca, Raquel Lopez, Alexandre André Balieiro Anastácio da Costa, Louise De Brot, Juan Pablo Molina, Laura Barboza, Fernanda Maris Peria, Fernando Chaud, Ana Silvia Gouvêa Yamada, Andres Poveda, Eduardo Magalhães Rego
BACKGROUND: Ovarian clear cell carcinomas (OCCCs) are rare, aggressive and chemoresistant tumors. Geographical and ethnic differences in the incidence of OCCC have been reported with a higher incidence in Asiatic countries. There is a paucity of information regarding OCCC in Latin America (LA) and other countries. METHODS: Here, we characterized two cohorts of 33 patients with OCCC from LA (24 from Brazil and 9 from Costa Rica) and a cohort of 27 patients from Spain...
July 3, 2023: BMC Cancer
https://read.qxmd.com/read/37364234/normalized-lst-is-an-efficient-biomarker-for-homologous-recombination-deficiency-and-olaparib-response-in-ovarian-carcinoma
#11
JOURNAL ARTICLE
Yann Christinat, Liza Ho, Sophie Clément, Catherine Genestie, Jalid Sehouli, Saverio Cinieri, Antonio Gonzalez Martin, Ursula Denison, Keiichi Fujiwara, Ignace Vergote, Germana Tognon, Sakari Hietanen, Isabelle Ray-Coquard, Eric Pujade-Lauraine, Thomas A McKee
PURPOSE: The efficiency of the Myriad Homologous Recombination Deficiency (HRD) test to guide the use of poly (ADP-ribose) polymerase (PARP) inhibitors has been demonstrated in several phase III trials. However, a need exists for alternative clinically validated tests. METHODS: A novel biomarker for HRD was developed using The Cancer Genome Atlas database and, as part of the ENGOT HRD European Initiative, applied to 469 samples from the PAOLA-1/ENGOT-ov25 trial...
June 2023: JCO Precision Oncology
https://read.qxmd.com/read/37309001/mfi2-upregulation-promotes-malignant-progression-through-egf-fak-signaling-in-oral-cavity-squamous-cell-carcinoma
#12
JOURNAL ARTICLE
Wei-Chen Yen, Kai-Ping Chang, Cheng-Yi Chen, Yenlin Huang, Ting-Wen Chen, Hsing-Wen Cheng, Jui-Shan Yi, Chun-Chia Cheng, Chih-Ching Wu, Chun-I Wang
Oral squamous cell carcinoma (OSCC) is the predominant histological type of the head and neck squamous cell carcinoma (HNSCC). By comparing the differentially expressed genes (DEGs) in OSCC-TCGA patients with copy number variations (CNVs) that we identify in OSCC-OncoScan dataset, we herein identified 37 dysregulated candidate genes. Among these potential candidate genes, 26 have been previously reported as dysregulated proteins or genes in HNSCC. Among 11 novel candidates, the overall survival analysis revealed that melanotransferrin (MFI2) is the most significant prognostic molecular in OSCC-TCGA patients...
June 12, 2023: Cancer Cell International
https://read.qxmd.com/read/37296748/homologous-recombination-deficiency-score-determined-by-genomic-instability-in-a-romanian-cohort
#13
JOURNAL ARTICLE
Viorica-Elena Rădoi, Mihaela Țurcan, Ovidiu Virgil Maioru, Andra Dan, Laurentiu Camil Bohîlțea, Elena Adriana Dumitrescu, Adelina Silvana Gheorghe, Dana Lucia Stănculeanu, Georgia Thodi, Yannis L Loukas, Ileana-Delia Săbău
The Homologous Recombination Deficiency (HRD) Score, determined by evaluating genomic instability through the assessment of loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large-scale state transitions (LST), serves as a crucial biomarker for identifying patients who might benefit from targeted therapies, such as PARP inhibitors (PARPi). This study aimed to investigate the efficacy of HRD testing in high-grade serous ovarian carcinoma, tubal, and peritoneal cancer patients who are negative for somatic BRCA1 and BRCA2 mutations and to evaluate the impact of HRD status on Bevacizumab and PARPi therapy response...
May 29, 2023: Diagnostics
https://read.qxmd.com/read/37088333/biallelic-eloc-inactivated-renal-cell-carcinoma-molecular-features-supporting-classification-as-a-distinct-entity
#14
JOURNAL ARTICLE
Aashil A Batavia, Dorothea Rutishauser, Bettina Sobottka, Peter Schraml, Niko Beerenwinkel, Holger Moch
Approximately 70% of clear cell renal cell carcinoma (ccRCC) is characterized by the biallelic inactivation of von Hippel-Lindau (VHL) on chromosome 3p. ELOC-mutated (Elongin C-mutated) renal cell carcinoma containing biallelic ELOC inactivations with chromosome 8q deletions is considered a novel subtype of renal cancer possessing a morphologic overlap with ccRCC, renal cell carcinoma (RCC) with fibromyomatous stroma exhibiting Tuberous Sclerosis Complex (TSC)/mammalian Target of Rapamycin (mTOR) mutations, and clear cell papillary tumor...
August 2023: Modern Pathology
https://read.qxmd.com/read/37048158/copy-number-variation-in-inflammatory-breast-cancer
#15
JOURNAL ARTICLE
Aditi Hazra, Andrea O'Hara, Kornelia Polyak, Faina Nakhlis, Beth T Harrison, Antonio Giordano, Beth Overmoyer, Filipa Lynce
Identification of a unique genomic biomarker in de novo inflammatory breast cancer (IBC) may provide an insight into the biology of this aggressive disease. The goal of our study was to elucidate biomarkers associated with IBC. We examined breast biopsies collected from Dana-Farber Cancer Institute patients with IBC prior to initiating preoperative systemic treatment (30 samples were examined, of which 14 were eligible). Patients without available biopsies ( n = 1), with insufficient tumor epithelial cells ( n = 10), or insufficient DNA yield ( n = 5) were excluded from the analysis...
April 4, 2023: Cells
https://read.qxmd.com/read/36966951/clonal-and-intrinsic-heterogeneity-of-somatic-variants-in-microsatellite-stable-colorectal-carcinomas-and-their-metastases
#16
JOURNAL ARTICLE
Maja Hühns, Najim Ameziane, Carsten Holzmann, Ruslan Al-Ali, Friedrich Prall
To test the traditional model of tumor progression, Darwinian-type evolution, against the more recent Big Bang model, we selected six microsatellite-stable colorectal standard-type adenocarcinomas and their synchronous lymph node and liver metastasis. Somatic genomic variants were identified by whole exome sequencing of large tumor fragments from the primaries and one liver metastasis each and used to design targeted resequencing NGS panels, one per case. Targeted deep resequencing (mean coverage 2725/median 2222) was done with DNA from punch samples (1 mm tissue microarrayer needles) obtained from different regions of the primaries and their metastases...
March 24, 2023: Laboratory Investigation; a Journal of Technical Methods and Pathology
https://read.qxmd.com/read/36917897/integrated-genetic-profiling-of-archival-pediatric-high-grade-glial-tumors-and-reassessment-with-2021-who-classification-of-paediatric-cns-tumours
#17
JOURNAL ARTICLE
Linda D Cooley, Lisa A Lansdon, Kris Laurence, John C Herriges, Lei Zhang, Elena A Repnikova, Julie Joyce, Preeti Thakor, Lisa Warren, Scott C Smith, Byunggil Yoo, Melissa Gener, Kevin F Ginn, Midhat S Farooqi
Though rare, pediatric high-grade gliomas (pHGG) are a leading cause of cancer-related mortality in children. We wanted to determine whether our currently available clinical laboratory methods could better define diagnosis for pHGG that had been archived at our institution for the past 20 years (1998 to 2017). We investigated 33 formalin-fixed paraffin-embedded pHGG using ThermoFisher Oncoscan SNP microarray with somatic mutation analysis, Sanger sequencing, and whole genome sequencing. These data were correlated with historical histopathological, chromosomal, clinical, and radiological data...
June 2023: Cancer Genetics
https://read.qxmd.com/read/36865331/genomic-analyses-of-germline-and-somatic-variation-in-high-grade-serous-ovarian-cancer
#18
Aaron W Adamson, Yuan Chun Ding, Linda Steele, Lucile A Leong, Robert Morgan, Mark T Wakabayashi, Ernest S Han, Thanh H Dellinger, Paul S Lin, Amy A Hakim, Sharon Wilczynski, Charles D Warden, Shu Tao, Victoria Bedell, Mihaela C Cristea, Susan L Neuhausen
Background High-grade serous ovarian cancers (HGSCs) display a high degree of complex genetic alterations. In this study, we identified germline and somatic genetic alterations in HGSC and their association with relapse-free and overall survival. Using a targeted capture of 577 genes involved in DNA damage response and PI3K/AKT/mTOR pathways, we conducted next-generation sequencing of DNA from matched blood and tumor tissue from 71 HGSC participants. In addition, we performed the OncoScan assay on tumor DNA from 61 participants to examine somatic copy number alterations...
February 20, 2023: Research Square
https://read.qxmd.com/read/36788060/comparative-molecular-genetics-of-odontogenic-keratocysts-in-sporadic-and-syndromic-patients
#19
JOURNAL ARTICLE
Melvin A Ambele, Liam Robinson, Marlene B van Heerden, Michael S Pepper, Willie F P van Heerden
Odontogenic keratocysts (OKCs) are common cysts of odontogenic origin that usually occur as a single nonsyndromic cyst in isolation (sporadic) or as syndromic multiple cysts as a manifestation of naevoid basal cell carcinoma syndrome. Alterations involving the PTCH gene are the most commonly identified factor associated with up to 85% and 84% of naevoid basal cell carcinoma syndrome and sporadic cases, respectively. Other Hedgehog pathway and non-Hedgehog pathway-associated genes have been implicated in the pathogenesis of OKCs...
January 2023: Modern Pathology
https://read.qxmd.com/read/36765597/follicular-thyroid-adenoma-and-follicular-thyroid-carcinoma-a-common-or-distinct-background-loss-of-heterozygosity-in-comprehensive-microarray-study
#20
JOURNAL ARTICLE
Martyna Borowczyk, Paula Dobosz, Ewelina Szczepanek-Parulska, Bartłomiej Budny, Szymon Dębicki, Dorota Filipowicz, Elżbieta Wrotkowska, Michalina Oszywa, Frederik A Verburg, Małgorzata Janicka-Jedyńska, Katarzyna Ziemnicka, Marek Ruchała
Pre- and postsurgical differentiation between follicular thyroid adenoma (FTA) and follicular thyroid cancer (FTC) represents a significant diagnostic challenge. Furthermore, it remains unclear whether they share a common or distinct background and what the mechanisms underlying follicular thyroid lesions malignancy are. The study aimed to compare FTA and FTC by the comprehensive microarray and to identify recurrent regions of loss of heterozygosity (LOH). We analyzed formalin-fixed paraffin-embedded (FFPE) samples acquired from 32 Caucasian patients diagnosed with FTA (16) and FTC (16)...
January 19, 2023: Cancers
keyword
keyword
104322
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.